Integrated Platform of siRNA Drug Discovery
RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality. To accelerate the discovery of novel siRNAs, WuXi AppTec has established an integrated platform encompassing siRNA sequence design, chemical synthesis/modification, delivery ligand exploration, and activity/off-target assessment.
At the TIDES USA 2024 Conference, our scientists presented a poster showcasing the effectiveness of this platform in conducting a comprehensive study on complement component 5 (C5) siRNAs, identifying chemically modified C5-targeting siRNAs that exhibit potent inhibition of C5 mRNA with minimal off-target effects.

TIDES USA Poster_Integrated Platform of siRNA Drug Discovery
Related Content
Strategies for Novel Autoimmune Drug Development: Preclinical Efficacy and Case Studies of JAK-STAT Targeted Therapies JAK Family Molecules: Central Hubs...
VIEW RESOURCEAccelerating SLE Drug Discovery: A Short-Term BM12-Induced Mouse Model for Efficient Drug Screening Systemic lupus erythematosus (SLE) is a chronic...
VIEW RESOURCE
